利培酮与奎硫平治疗精神分裂症的成本-效果分析  

Cost-effectiveness Analysis of Risperidone and Quetiapine in the Treatment of Schizophrenia

作　　者：陶建青[1] 石捷[1] 康红[1] 梁佳[1] 业明[1] 朱澜[1] 曾强[1] 

机构地区：[1]广西壮族自治区人民医院,南宁市530021

出　　处：《中国药房》2005年第9期678-679,共2页China Pharmacy

摘　　要：目的研究利培酮与奎硫平治疗精神分裂症的经济学效果。方法将64例精神分裂症患者随机分为利培酮组(34例)与奎硫平组(30例),以简明精神病评定量表(BPRS)评分减少量来评价效果,以不良反应量表(TESS)评分评定不良反应,并进行成本-效果分析。结果利培酮组与奎硫平组人均成本分别为3598.85元、3778.63元,BPRS评分减少量分别为(36.09±15.52)、(25.03±14.45),成本-效果比分别为99.72元、150.96元,奎硫平组相对于利培酮组的增量成本-效果比为—16.25。结论治疗精神分裂症利培酮是较为经济的药物。OBJECTIVE:To study the econamics effect of risperidone and quetiapine in treating of schizophrenia.METH ODS:64schizophrenia patients were randomly divided into risperidone group(34cases)and quetiapine group(30cases).The effects were evaluated based on the reduction of scores determined by brief psychiatric rating scale(BPRS);the adverse effects were evaluated by treatment emergent symptom scale(TESS).And then the cost-effectiveness analysis was carried through.RESULTS:The per capita costs for risperidone and quetiapine were3598.85yuan and3778.63yuan respectively;the re-duction of BPRS scores were(36.09±15.52)and(25.03±14.45)respectvely;the respective cost-effect ratio was99.72yuan and150.96yuan;the increment of the cost-effect ratio for the quetiapine group was-16.25compared with the risperidone group.CONCLUSION:Risperidone is more economical than quetiapine in the treatment of schizophrenia.

关 键 词：利培酮 奎硫平 成本-效果分析 

分 类 号：R956[医药卫生—药学]